Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors

2009 ◽  
Vol 84 (10) ◽  
pp. 688-689 ◽  
Author(s):  
Cristina Alencar ◽  
Matthew Abramowtiz ◽  
Samir Parekh ◽  
Ira Braunshweig ◽  
Mark Jacobson ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Sweet’S Syndrome ◽  
Hypomethylating Agents ◽  
Sweet's Syndrome ◽  
Atypical Presentations

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2655-2655
Author(s):  
Elias Jabbour ◽  
Susan O’Brien ◽  
Farhad Ravandi-Kashani ◽  
Jorge Cortes ◽  
Gautam Borthakur ◽  
...  
Keyword(s):  
Growth Factors ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Chromosomal Abnormalities ◽  
Chronic Myelomonocytic Leukemia ◽  
Study Group ◽  
Hypomethylating Agents ◽  
Future Studies ◽  
Prior Therapy ◽  
Myelomonocytic Leukemia

Abstract Background The hypomethylating agents decitabine and azacitidine have significant anti-myelodysplastic (MDS)activity and have been FDA approved for the treatment of MDS and CMML. Experience in CMML has been minimal. Study Aims Evaluate the efficacy of decitabine in CMML. Study Group and Treatment Patients with CMML received decitabine 20 mg/m2 IV/1 hour daily x 5 or 2 alternative schedules, delivering 100 mg/m2/course every four weeks (Kantarjian, Blood 2006). Response was evaluated by the modified IWG criteria (Cheson, Blood 2006). Results Nineteen patients were treated. Their median age was 66 years (range 44–82 years). Splenomegaly was present in 4 (21%); hemoglobin less than 10 g/dL in 10 (53%); thrombocytopenia less than 100 x 109/L in 12 (63%); WBC more than 40 x 109/L in 5 (26%); chromosomal abnormalities in 6 (32%); prior therapy for CMML in 9 (47%); marrow or peripheral blast 5% or more in 11 (58%). Overall, 13 patients (69%) achieved IWG responses: CR in 11 (58%), other HI in 2 (11%). Improvement of thrombocytopenia was noted in 7/8 patients (88%) with pretreatment platelets less than 50 x 109/L. Median survival was 19 months. Among 6 patients with pretreatment chromosomal abnormalities who achieved response, 1 (17%) had disappearance, and 2 had > 50% reduction of cytogenetic abnormalities. Extramedullary toxicities were minimal. Conclusions Decitabine is active and safe in CMML. Future studies may combine decitabine with histone deacetylase inhibitors, chemotherapy (eg cytarabine, topotecan), or growth factors.

scholarly journals The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

2015 ◽  
Vol 171 (2) ◽  
pp. 215-226 ◽  
Author(s):  
Enrica Marchi ◽  
Kelly M. Zullo ◽  
Jennifer E. Amengual ◽  
Matko Kalac ◽  
Danielle Bongero ◽  
...  
Keyword(s):  
T Cell ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Hypomethylating Agents ◽  
Preclinical Models

Sweet's syndrome associated with Salmonella enteritidis infection

1999 ◽  
Vol 24 (3) ◽  
pp. 239-240 ◽  
Author(s):  
Flórez ◽  
Sánchez-Aguilar ◽  
Rosón ◽  
Prieto ◽  
Van den Eyden ◽  
...  
Keyword(s):  
Salmonella Enteritidis ◽  
Sweet’S Syndrome ◽  
Sweet's Syndrome

Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with Waldenstroem's macroglobulinemia.

1990 ◽  
Vol 52 (5) ◽  
pp. 901-905
Author(s):  
Yoshihiro UMEBAYASHI ◽  
Hiromasa NAMEKI ◽  
Yoshio SAITO ◽  
Ryushi TAZAWA ◽  
Yuji OKA ◽  
...  
Keyword(s):  
Neutrophilic Dermatosis ◽  
Sweet’S Syndrome ◽  
Sweet's Syndrome ◽  
Acute Febrile Neutrophilic Dermatosis
Sign in / Sign up

Export Citation Format

Share Document